Upload
apoorvamandavilli
View
224
Download
0
Embed Size (px)
Citation preview
8/8/2019 Don't Rush Your Vaccines
1/3
7/30/10 4:on't rush your vaccines : Nature News
Page ttp://www.nature.com/news/2007/070517/full/news070514-15.html
Published online 17 May 2007 | Nature | doi:10.1038/news070514-15
Column
Don't rush your vaccines
The ethical debate about a vaccine for a sexually transmitted disease
has been premature, says Apoorva Mandavilli; we don't even know howell it works.
Apoorva Mandavilli
Here's a good lesson: before you start pushing for a controversial vaccine to be made compulsory
best wait for the research and I mean all the research to come up with results.
For more than a year, we've been hearing that there is a vaccine that is 100% safe and effective in
protecting young girls and women from the deadly viruses that cause cervical cancer.
Merck's Gardasil, a vaccine against human papilloma virus (HPV), has been hailed as perhaps the
biggest boon for women since the contraceptive pill. Across the world, including many American
states, politicians and activists have proposed laws to make Gardasil mandatory for girls in their
early teens or younger. Australia has already started a national programme of free vaccines for
young girls.
All that sounds a bit premature and rightly so. As we find out more about this vaccine, includin
new studies in last week'sNew England Journal of Medicine1,2, it's clear we simply don't know
enough about it to be giving it to young girls en masse.
It's not that I think vaccinating young girls will encourage them to become promiscuous, as some
conservative groups have argued. And I'm not going to question Merck's motives in pushing this
vaccine because, well, what else do we expect pharmaceutical companies to do with their product
I'm also not contesting that the vaccine is great at what it sets out to do: in trials, it was nearly
100% effective at preventing infection with the two strains of HPV (16 and 18), which cause abou70% of cervical cancers. It also seems to protect from two other strains that cause genital warts.
But that's not all we need to know.
Good for the young?
For example, because the initial trials tested the vaccine in women aged 16-26 over five years, we
http://www.nature.com/news/2007/070517/full/news070514-15.html#B2http://www.nature.com/news/2007/070517/full/news070514-15.html#B18/8/2019 Don't Rush Your Vaccines
2/3
7/30/10 4:on't rush your vaccines : Nature News
Page ttp://www.nature.com/news/2007/070517/full/news070514-15.html
ADVERTISEMENT
don't know for sure that the vaccine is effective in girls younger than 16, nor whether its effect
and safety will last longer than five years (see 'Controversy over cervical cancer vaccine
spurs safety surveillance ').
Another important piece of fine print: the vaccine is most effective before women are sexually
active.
When scientists tested the vaccine in more than 18,000 women in two further trials, most of
whom were already sexually active, the vaccine's effectiveness fell to less than 20% a modest
protection at best1,2.
That's at least partly because some of those women were already infected with the virus strains
that the vaccine is designed against. It might also be because the vaccine, by blocking four strains
allows other strains to flourish which could negate the vaccine's benefit.
When we don't know the answers to so many questions, why are we in such a rush to make the
jabs mandatory?
Good for the rich
Let's leave aside for the moment that only a fraction of cervical cancer cases in the world occur in
countries where the debate is ongoing (that is developed nations), thanks in part to Pap smears,
which can detect pre-cancerous conditions before they develop into full-blown cervical cancer.
More than 80% of cervical cancer cases expected to increase to 90% by 2020 are in
developing countries, which can't afford the pricey jab or the pap smear.
At the moment, the vaccine costs US$360 for the three required doses. Having governments
provide the vaccine for free to millions of women and girls would add up to an enormous amount
That money might be better spent providing Pap smears to the women who can't afford them or a
least diverted to more urgent health needs.
In the meantime, I do think the vaccine should be
given but with caution and perhaps only in girls and
women who we know are not yet infected with two
deadliest strains. Merck and GlaxoSmithKline, whichalso has a HPV vaccine in the works, are working on
adding more of 20 known strains to their vaccines.
Merck is also tracking Gardasil's long-term effects in
the 40,000 women who have received it.
To be fair, the latest studies have only tracked three
http://www.nature.com/news/2007/070517/full/news070514-15.html#B2http://www.nature.com/news/2007/070517/full/news070514-15.html#B1http://www.nature.com/news/2007/070326/full/nm0407-392b.htmlhttp://ad.doubleclick.net/click;h=v8/39e7/0/0/%2a/r;225429760;0-0;0;9916591;4307-300/250;36982058/36999936/1;;~sscs=%3fhttp://www.nature.com/nchembio/journal/v6/n6/full/nchembio.379.html8/8/2019 Don't Rush Your Vaccines
3/3
7/30/10 4:on't rush your vaccines : Nature News
Page ttp://www.nature.com/news/2007/070517/full/news070514-15.html
About NPG
Contact NPG
RSS web feeds
Help
Privacy policy
Legal notice
Accessibility statement
Terms
Nature News
Naturejobs
Nature Asia
Nature Education
About Nature News
Nature News Sitemap
Search: go
Nature ISSN 1744-7933 EISSN 1476-4687
years of data, and after a longer follow up the vaccine
might well prove to be worth all the hype. Then again,
it might not. But until we have enough information to
decide, let's admit we just don't know.
Visit our rushyour_vaccines.html">newsblog to read and post comments about this
story.
References
1. The FUTURE II Study Group.N. Engl. J. Med., 356 . 1915 - 1927 (2007).
2. The FUTURE II Study Group.N. Engl. J. Med., 356 . 1928 - 1943 (2007).
2010 Nature Publishing Group, a division of Macmillan Publishers Limited. AllRights Reserved.
partner ofAGORA, HINARI, OARE, INASP, CrossRef and COUNTER
http://www.nature.com/info/partners.htmlhttp://www.nature.com/info/copyright_statement.htmlhttp://blogs.nature.com/news/blog/2007/05/dont%3Cspan%20class=http://ad.doubleclick.net/click;h=v8/39e7/0/0/%2a/r;225429760;0-0;0;9916591;4307-300/250;36982058/36999936/1;;~sscs=%3fhttp://www.nature.com/nchembio/journal/v6/n6/full/nchembio.379.htmlhttp://www.nature.com/news/about-this-site.htmlhttp://www.nature.com/news/about-us.htmlhttp://www.nature.com/scitable/http://www.natureasia.com/http://www.nature.com/naturejobs/http://www.nature.com/news/http://www.nature.com/info/tandc.htmlhttp://www.nature.com/info/accessibility_statement.htmlhttp://www.nature.com/info/legal_notice.htmlhttp://www.nature.com/info/privacy.htmlhttp://www.nature.com/help/http://www.nature.com/webfeeds/http://www.nature.com/npg_/contact/http://www.nature.com/npg/